1. Review pre-clinical data establishing the role of the microbiome in affecting response to immunotherapy (IO).
  2. Review clinical evidence associating antibiotic use with inferior response to immunotherapy.
  3. Discuss challenges and future directions. 


  1. To review evidence for CTDNA assays in the clinical setting
  2. To highlight barriers to more widespread use of CTDNA assays
  3. To discuss possible solutions for these barriers
Session date: 
07/16/2018 - 12:00pm to 1:00pm CDT
5841 South Maryland Avenue
MC2115 HemOncConference Room E-215
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Afaf Osman, MD and Padma Sheila Ragajopal, MD, MPH